Lupin Limited · NSE:LUPIN
Lupin — Investor Meet 2025
30 slides from Lupin's conference presentation, May 15, 2025
Slide 1: Exchange filing cover letter for Investor Presentation
May 15, 2025 National Stock Exchange of India Limited BSE Limited Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Mumbai Samachar Marg, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Investor Presentation - Investors Meet 2025. D
Slide 2: Investor Meet 2025
Investor Meet 2025 May 15, 2025 1
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this and patents obtained by other pharmaceutical cautioned not to place undue reliance on these presentation may contain forward looking companies. Challenges inherent in new product forward- looking statements, which reflect our state
Slide 4: Lupin Today
Lupin Today 3
Slide 5: Lupin Today
Lupin Today Global Presence Local Leadership Geographically Diverse Growing Sustainability India United States 3rd Largest In the US (by prescriptions ) 2 12th $2.7 Bn 75,773 79,975 34% 36% 8th India Pharma Market Rank (by sales4) Largest Generic Annual sales Top 10% Company in FY256 4th Largest Aus
Slide 6: Global Footprint
Global Footprint USFDA Plants 15 Manufacturing Sites Goa Pithampur Unit – I, II, III • Capacity for >30 billion units Somerset • Finished Dosage, API, Biologics Nagpur Unit – I, II Dabhasa Mandideep Unit – I, II 7 R&D Centers Ankleshwar Manufacturing sites Research & Development Tarapur • State-of-t
Slide 7: Catalyzing Treatments that serve Patients around the world
Catalyzing Treatments that serve Patients around the world United Other Developed Other Emerging India API States Markets Markets Evolving portfolio and Driving operating Delivering above- Global reach and scale Substantial scale pipeline in Complex leverage in Portfolio, market growth. positions us
Slide 8: Lupin Journey in last 5 years
Lupin Journey in last 5 years Commercial Excellence New Product Launches Consistent improvement in performance • Turnaround of US business Launched 200+ Products 250 66% 69% 70.0% 64% 64% • 1st Indian Company to launch DPI in the US; scale 60% 58% 60.0% • Suprep, Albuterol, gSpiriva, 200 in Respirat
Slide 9: Key Growth Metrics
Key Growth Metrics Continued Strong Operating Performance in FY25 Key Metrics Business Performance Values in INR unless indicated otherwise 221,921 mn Sales APAC 12.9% YoY India 11,860 mn | 5% YoY 75,773 mn | 14% YoY 52,775 mn EBITDA1 23.8% LATAM 38.9% YoY Margin North America 7,709 mn | 10% YoY 83,
Slide 10: Evolving Trends in Global Pharma Industry
Evolving Trends in Global Pharma Industry Indian Pharma industry India opportunity is pivoting Geopolitical tensions to continue Rising impact of AI across poised to grow 2.2x in next 5 from Pharma only to overall shaping global landscape industries, including pharma years Healthcare 1. 4. 5. 8. • C
Slide 11: Our Core Growth Platforms
Our Core Growth Platforms Best in Class Sustain India Region Expand Inhalation & Deliver NPLs on-time Establish Specialty Compliance and US Growth drive green propellant & on-budget business products Leverage Digital and AI Strong People Establish Injectables & Establish Novel Build scale across Imp
Slide 12: Business Overview
1 LUPIN Business Overview
Slide 13: US: Developing a Balanced & Diversified Presence
US: Developing a Balanced & Diversified Presence Brief Overview Continued trajectory of growth Growing focus on Complex & Specialty Products Key Growth drivers - Complex Gx NPLs & Specialty • Net Sales ~$925 M (FY25), YoY Growth ~13% • Growth led by Complex Generics • #3 in US Gx market1 Gx, NPLs 21
Slide 14: India Region Formulations: Focus on Chronic
India Region Formulations: Focus on Chronic Brief Overview Strong underlying growth ex-IL Portfolio3 Focus on Chronic Conditions Aspiration to grow at 1.2-1.3x of IPM growth • #8 Rank1 in Overall Indian Pharma Enhancing Reach & coverage, Omnichannel 18.5% touchpoints & expansion (2,000+ ME’s in next
Slide 15: Other Developed Markets: Overview & Growth Strategy
Other Developed Markets: Overview & Growth Strategy Europe Canada Australia CGx & Specialty Portfolio expansion Specialty driven Business Partnerships & B2B Sales ~USD 195 Mn Net Sales in FY25 ~USD 47 Mn Net Sales in FY25 ~USD 78 Mn Net Sales in FY25 ~14% CAGR b/w FY20-251 18% CAGR b/w FY20-252 #4 R
Slide 16: Other Emerging Markets: Overview & Growth Strategy
Other Emerging Markets: Overview & Growth Strategy South Africa Philippines Mexico Brazil GIB ~USD 83 Mn Net Sales in FY25 ~USD 42 Mn Net Sales in FY25 ~USD 49 Mn Net Sales in FY25 #1 Rank1 in Cardiovascular TA ~USD 39 Mn Net Sales in FY25 #3 Rank4 in Retail Reference #3 Rank3 in Ophthalmic TA #2 Ra
Slide 17: Evolving Adjacencies
Evolving Adjacencies Lupin Life Lupin Manufacturing Sciences Ltd Solutions YoY Revenue growth; Fastest amongst 44% peers to reach Rs 100 Cr. INR 1.5 Bn Annual revenue; committed to strong double-digit growth Support across the cardiac continuum with flagship LYFE® offering Launched in July 2024 to i
Slide 18: R&D & Portfolio
R&D & Portfolio 17
Slide 19: Evolving Product Development and Delivery Capabilities
Evolving Product Development and Delivery Capabilities Specialty Biosimilars Delivering a suite of 505(b)(2)s and Value- Commercial momentum Added Medicines – LAIs, ex-US and evolving commercial Oral Solids, Green Propellants capabilities in the US backed by inhouse R&D and manufacturing Complex Inj
Slide 20: Complex Platforms Driving Diversification of Global Generics
Complex Platforms Driving Diversification of Global Generics Revenue Split FY20 FY25 FY30E 2% 34% 55% FY25 FY30E 98% 66% 45% 9% 55% 67% Complex Platforms1 Others 45% 91% 33% Includes Specialty US Product Events Brovana & Budesonide Albuterol Brovana Xopenex Formoterol Tiotropium 8/2020 6/2021 acquis
Slide 21: Upcoming Key Launches in Developed Markets
Upcoming Key Launches in Developed Markets US market unless specified # of Products in # of Products in Platform Market Pipeline FY26 FY27 FY28 FY29 FY30 (Net Sales in USD Mn) (Market Size in USD Bn)1 MDI-1 DPI-1 12+ ~30 DPI-2 Inhalation NS-1 NS-2 MDI-4 (350+) (20+) MDI-3 MDI-2 (Canada) SMI-1 Glucag
Slide 22: Quality
Quality 21
Slide 23: US FDA Inspection Status & Our Quality Goals
US FDA Inspection Status & Our Quality Goals USFDA Inspection Status Focus on improving Regulatory Compliance Plant Type Plant Sites Plant Type Plant Sites Goa # of Plants under USFDA remediation Pithampur Unit – I Pithampur Unit – I Pithampur Unit – Il Formulations Mandideep Unit – I Pithampur Unit
Slide 24: Delivering Across the TechOps Value Chain
Delivering Across the TechOps Value Chain Established Global Technical Operations (GTO) function by integrating Manufacturing, Supply Chain & Procurement Customer Focus & Growth Cost Leadership Technology Leadership • OTIF improved to 100% in FY25 for US & • Achieved cost savings of ~USD 50+ mn • To
Slide 25: Key Financial Highlights
Key Financial Highlights 24
Slide 26: P&L Highlights Q4 FY25 & FY25
P&L Highlights Q4 FY25 & FY25 Amount in INR mn Q ’FY % of Sales Q ’FY % of Sales YoY Growth FY25 % of Sales FY24 % of Sales YoY Growth Net Sales 55,622 100.0% 48,951 100.0% 13.6% 221,921 100.0% 196,563 100.00% 12.9% Other operating 1,049 1.9% 657 1.3% 59.8% 5,158 2.3% 3,545 1.8% 45.5% income Total r
Slide 27: Key Financial Metrics (FY20-FY25)
Key Financial Metrics (FY20-FY25) Total Revenue (INR bn) Gross Margin % EBITDA & Margin % (INR bn) 17% CAGR 75% CAGR 69.2% 66.2% 23.8% 64.1% 64.1% 17.8% 19.3% 227 200 60.0% 15.6% 164 166 13.0% 10.6% 154 152 58.3% 53 24 27 21 38 17 FY20 FY21 FY22 FY23 FY24 FY25 FY20 FY21 FY22 FY23 FY24 FY25 FY20 FY21
Slide 28: Operational Excellence: Financial Improvements
Operational Excellence: Financial Improvements Lupin has achieved substantial financial improvements over the last five yeas through better working capital management, reduced leverage, and enhanced ROCE Improvement in NWC* Free Cash Flow* (INR bn) Debt-to-EBITDA ROCE Improvement* 27.2 0.22 0.20 21.
Slide 29: Lupin's ESG Update
Lup ’ E pd t Continuing to make consistent strides toward achieving our long-term ESG goals. Key Highlights ESG Goal Status FY 2025 Climate Change1 38% GHG Reduction by 2030 23% GHG Reduction Water 50% Recycling by 2030 44% Recycling Leadership rating in CDP 100% Indian Sites covered and "Silver Med
Slide 30: Thank You
Thank You Registered Address 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai - 400055, India Phone: +91 22664 02323 Fax: +91 22664 02051 lupin.com youtube.com/c/LupinGlobal x.com/LupinGlobal facebook.com/LupinWorld/ linkedin.com/company/lupin